content_top
43 companies, 1 interpreter! Insight, foresight
and recommendation 

Stemline Therapeutics, Inc. (STML)

9.80
0.20
(2.08%)
Sep 11, 4:00PM EDT
content_middle

Stemline Therapeutics (STML) a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercialization of proprietary oncology therapeutics.
 

STML develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which is in Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm, myeloproliferative neoplasms, and acute myeloid leukemia; and in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma. It also develops SL-801, a novel oral small molecule reversible inhibitor of a tumor-promoting nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that is in Phase II clinical trial to attack brain cancer.

STML also develops SL-501, a next generation IL-3R-targeted therapy that is in preclinical development.

Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.

Previous Close: 
9.60
Open: 
9.65
Bid: 
7.05
Ask: 
10.40
1yr Target Price: 
28.67
Day's Range: 
9.25 - 9.95
52wk Range: 
5.50 - 14.60
Volume: 
176999
Average Daily Volume: 
206084
Market Capitalization: 
229.86M
Trailing Annual Dividend Yield: 
N/A
Shares Outstanding: 
23455000M
content_right

Pages